Latest Breaking News On - Stephen nishimura - Page 1 : comparemela.com

Form 10-K Corbus Pharmaceuticals For: Dec 31

Form 10-K Corbus Pharmaceuticals For: Dec 31
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesUnited kingdomSan franciscoCredit onSean moranStephen nishimuraJohn jenkinsBristol meyersYuval cohenEli lillyRachelle jacquesAvery catlinAnne altmeyerPeter salzmannAlan holmerYong ben

Corbus Pharmaceuticals Licenses Two Integrin Targeting mAbs

Corbus diversifies pipeline with two new mAbs that target integrins that inhibit activation of TGFβ High potency anti-αvβ8 mAb licensed from University.

Anthony francisStephen nishimuraYuval cohenTechnology managementPanorama research incUniversity of california san franciscoCorbus pharmaceuticals holdings incCalifornia san franciscoPanorama researchPharmaceuticals holdingsExecutive directorChief executiveWebcast informationNasdaq crbpCorbus pharmaceuticals holdingsCorbus pharmaceuticals holding

Corbus Pharmaceuticals Licenses Two Integrin Targeting mAbs Further Expanding Pipeline into Cancer and Fibrotic Diseases

Corbus Pharmaceuticals Licenses Two Integrin Targeting mAbs Further Expanding Pipeline into Cancer and Fibrotic Diseases
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesUniversity of california san franciscoSan franciscoLindsey smithAnthony francisStephen nishimuraTed jenkinsYuval cohenEllen katsUniversity of californiaPanorama research incBusiness development licensingCorbus pharmaceuticals holdings incExchange commissionTechnology managementCorbus pharmaceuticals contacts

Corbus in licensing deal for monoclonal antibodies to tackle cancer and fibrotic diseases

Corbus Pharmaceuticals announced the expansion of its portfolio into immuno-oncology through licensing deals with the University of California San Francisco and Panorama Research Inc for two new monoclonal antibodies (mAbs).

United statesStephen nishimuraPanorama research incUniversity of california san franciscoCalifornia san franciscoPanorama researchMarkets amp regulationsMonoclonal antibodyஒன்றுபட்டது மாநிலங்களில்பனோரமா ஆராய்ச்சி இன்க்பல்கலைக்கழகம் ஆஃப் கலிஃபோர்னியா சான் பிரான்சிஸ்கோகலிஃபோர்னியா சான் பிரான்சிஸ்கோபனோரமா ஆராய்ச்சிசந்தைகள் ஆம்ப் ஒழுங்குமுறைகள்